您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
Invivo anti-mouse PD-1 Recombinant mAb (S-R496)

Invivo anti-mouse PD-1 Recombinant mAb (S-R496)

货号: S0B1459
价格: 900
规格: 1mg
介绍: -
其他: -
产品规格
  • 分子别名

    Programmed cell death protein 1; Protein PD-1; mPD-1; CD279; Pd1; Pdcd1
  • 细胞定位

    Cell membrane
  • Accession

    Q02242
  • 克隆号

    S-R496
  • 抗体类型

    Rat mAb
  • 应用

    In vivo blocking of PD-1/PD-L signaling
  • 反应种属 ?

    Ms
  • 纯化方式

    Protein G
  • 浓度

    5 mg/ml
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    PBS pH7.4

  • 储存条件

    2 to 8 °C for 2 weeks under sterile conditions;

    -20 °C for 3 months under sterile conditions; 

    -80 °C for 24 months under sterile conditions.

    Please avoid repeated freeze-thaw cycles.

  • 稀释度

    [{"application": "ELISA", "dilution": "", "species": ""}, {"application": "Sandwich ELISA", "dilution": "", "species": ""}, {"application": "CLIA", "dilution": "", "species": ""}, {"application": "Lateral Flow", "dilution": "", "species": ""}, {"application": "Dot Blot", "dilution": "", "species": ""}, {"application": "WB", "dilution": "", "species": ""}, {"application": "IP", "dilution": "", "species": ""}, {"application": "IHC", "dilution": "", "species": ""}, {"application": "ICC", "dilution": "", "species": ""}, {"application": "IF", "dilution": "", "species": ""}, {"application": "ICFCM", "dilution": "", "species": ""}, {"application": "FCM", "dilution": "", "species": ""}, {"application": "mIHC", "dilution": "", "species": ""}, {"application": "ChIP", "dilution": "", "species": ""}]
背景介绍
  • This antibody recognizes the same epitope as clone 29F.1A12. Programmed cell death protein 1 (PD-1), also known as CD279, is a type I transmembrane protein and a member of the CD28 immunoglobulin superfamily. It is primarily expressed on the surface of various immune cells, including T cells, B cells, macrophages, dendritic cells, and natural killer cells. PD-1 plays a crucial role in regulating immune responses by binding to its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), which are expressed on antigen-presenting cells and tumor cells. When PD-1 interacts with its ligands, it triggers inhibitory signals that downregulate T cell activity, preventing excessive immune responses and promoting self-tolerance. However, this pathway can also be exploited by cancer cells to evade immune surveillance, leading to tumor progression. As a result, PD-1 has become a key target in cancer immunotherapy, with several anti-PD-1 antibodies approved for treating various cancers, achieving significant and durable efficacy in some patients.